TET2 downregulation enhances the antitumor efficacy of CD19 CAR T cells in a preclinical model.
Ontology highlight
ABSTRACT: Chimeric antigen receptor (CAR) T cell therapy has demonstrated significant clinical efficacy in patients with hematologic cancers. However, long-term follow-up studies indicate that only 50% of patients remain in complete remission after three years. To overcome these limitations, we investigated a strategy to enhance the antitumor activity of CAR T cells through gene modification. Based on previous research results demonstrating that CAR T cells with disrupted TET2, a methylcytosine dioxygenase, exhibit enhanced antitumor effects compared to conventional CAR T, we developed CAR T cells in which TET2 is downregulated by TET2 shRNA. Among the screened TET2-specific shRNAs, TET2-shRNA-1 was identified as the most effective sequence for gene silencing. Using this sequence, we constructed an
SUBMITTER: Kim Y
PROVIDER: S-EPMC11866829 | biostudies-literature | 2025 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA